Chiome Bioscience (TSE:4583) PEG Ratio: 0.00 (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4583 Chiome Bioscience Inc TSE:4583
38 GF Score
Price 円69.00
GF Value 円106.02
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Chiome Bioscience PEG Ratio?

Chiome Bioscience TSE:4583 -1.43% 38 PEG Ratio is 0.00 as of Jul. 25, 2026. GuruFocus rates TSE:4583 with a GF Score™ of 38/100 and a GF Value™ of 円106.02 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 94 Biotechnology companies, Chiome Bioscience ranks worse than 1063828.72% on this metric.

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Chiome Bioscience's PE Ratio without NRI is 0.00. Chiome Bioscience's 5-Year EBITDA growth rate is 15.70%. Therefore, Chiome Bioscience's PEG Ratio for today is 0.00.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Chiome Bioscience's PEG Ratio or its related term are showing as below:



TSE:4583's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.85
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Chiome Bioscience  (TSE:4583) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Chiome Bioscience PEG Ratio Related Terms


Chiome Bioscience PEG Ratio Historical Data

* Premium members only.

The historical data trend for Chiome Bioscience's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chiome Bioscience PEG Ratio Chart

Chiome Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Chiome Bioscience Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSE:4583 vs VRTX, REGN, ALNY: PEG Ratio Comparison

For the Biotechnology subindustry, Chiome Bioscience's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chiome Bioscience PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's PEG Ratio falls into.


TSE:4583
38GF Score
Chiome Bioscience Inc TSE:4583
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chiome Bioscience PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Chiome Bioscience's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/15.70
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Frequently Asked Questions Learn more about PEG Ratio →
What does a PEG Ratio of 0.00 mean?
Chiome Bioscience (TSE:4583) has a PEG Ratio of 0.00 as of Jul. 25, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Chiome Bioscience and its competitors. According to the industry distribution chart, Chiome Bioscience ranks #999999 out of 94 companies in the Biotechnology industry.
Is Chiome Bioscience's PEG Ratio too high?
Chiome Bioscience's current PEG Ratio is 0.00. Based on the distribution chart, Chiome Bioscience ranks #999999 out of 94 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chiome Bioscience has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chiome Bioscience ranks #999999 out of 94 companies for PEG Ratio. This places Chiome Bioscience in the lower half of its industry. The industry median PEG Ratio is 1.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.85, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Chiome Bioscience and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chiome Bioscience's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Possible Value Trap. The stock's GF Value™ is 円106.02, compared to a current price of 円69.00 — trading 34.9% below its estimated fair value. The current PEG Ratio is 0.00. Chiome Bioscience's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current PEG Ratio is 0.00 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chiome Bioscience (TSE:4583) Overvalued in 2026?

Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued. The current stock price of 円69.00 is trading 34.9% below its estimated GF Value™ of 円106.02. GuruFocus considers Chiome Bioscience to be Possible Value Trap.

Key valuation signals for TSE:4583:

  • PEG Ratio: 0.00
  • GF Value™: 円106.02 vs. price of 円69.00 (34.9% below fair value)
  • GF Score™: 38/100 with 1 warning sign

No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chiome Bioscience Business Description

Address 3-12-1 Honmachi, No. 6, Sumitomo Fudosan Nishi Shinjuku Building, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
38GF Score

Get the complete analysis for TSE:4583

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円69.00
Price
円106.02
GF Value